TrialCancer2019

Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Shunichi Sugawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.